THIS SUPPLEMENTAL AGREEMENT is made on 29 July 2011 BETWEEN:Conditional Stock Purchase Agreement • October 27th, 2011 • Wl Ross & Co LLC • Commercial banks, nec
THE MINISTER FOR FINANCE OF IRELAND of Upper Merrion Street, Dublin 2 (hereinafter called the "Minister") THE NATIONAL PENSIONS RESERVE FUND COMMISSION acting in its capacity as controller and manager of the assets of the National Pensions Reserve Fund of Treasury Building, Grand Canal Street, Dublin 2 (hereinafter called the "Commission") THE NATIONAL TREASURY MANAGEMENT AGENCY of Treasury Building, Grand Canal Street, Dublin 2 (hereinafter called the "NTMA") - and - THE PERSONS WHOSE NAMES ARE SET OUT IN SCHEDULE 1 TO THE CONDITIONAL STOCK PURCHASE AGREEMENT REFERRED TO HEREIN (hereinafter called the "Buyers")
CONDITIONAL STOCK PURCHASE AGREEMENTConditional Stock Purchase Agreement • November 10th, 2021 • Clean Energy Technologies, Inc. • Printed circuit boards • Nevada
THIS CONDITIONAL STOCK PURCHASE AGREEMENT (the “Agreement”), is made as of November 8, 2021, between the Clean Energy Technologies (H.K.) Limited., a wholly owned subsidiary of Clean Energy Technologies Inc. (CETY), incorporated in Hong Kong with a registered address at 22/F Ovest, No. 77 Wing Lok Street, Sheung Wan, Hong Kong(“Purchaser”)and Mr. Li Chin-kun, with an address at Flat F, 15/F, Blk T16, Yee Shan Mansion, 7 Tai Fung Avenue, Hong Kong(the “Seller”) with respect to 1ordinary share, par value $1 per share (the “Common Stock”), of Leading Wave Limited., a company incorporated in the Republic of Seychelles with the company number 218629 (“LWL”). (Seller and Purchaser may hereinafter be referred to singularly as a “party,” and collectively as the “parties.”)
CONDITIONAL STOCK PURCHASE AGREEMENT by and among SCOPUS BIOPHARMA INC. and THE SELLERS PARTY HERETO dated as of June 8, 2020 CONDITIONAL STOCK PURCHASE AGREEMENTConditional Stock Purchase Agreement • July 22nd, 2020 • Scopus BioPharma Inc. • Pharmaceutical preparations • New York
This CONDITIONAL STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of June 8, 2020, is entered into among (i) Scopus BioPharma Inc., a Delaware corporation (“Purchaser”), (ii) Bioscience Oncology Pty Ltd (ACN: 632 972 395), a corporation organized under the laws of Australia (the “Company”), (iii) Paul Hopper, an individual and the founder and initial shareholder of the Company (“Hopper”) and (iv) the additional parties who are signatories to this Agreement, each of whom is individually referred to as a “Seller” and collectively referred to as “Sellers”. Purchaser, the Company and the Sellers, are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
